LSTA / Lisata Therapeutics, Inc. - SEC Filings, Annual Report, Proxy Statement

Exhibit 10.3 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and James Nisco (“Executive”). WITNESSETH WHE

ex103arseparationbenefit Exhibit 10.3 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and James Nisco (“Executive”). WITNESSETH WHEREAS, the Company and Executive previously entered into the Prior Agreements (as defined in Section 1(f) below); and WHEREAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS, I

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call

Exhibit 99.1 Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, NJ (August 7, 2025) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or

Exhibit 10.4 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and Tariq Imam (“Executive”). WITNESSETH WHER

ex104arseparationbenefit Exhibit 10.4 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and Tariq Imam (“Executive”). WITNESSETH WHEREAS, the Company and Executive previously entered into the Prior Agreements (as defined in Section 1(f) below); and WHEREAS t

1 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025 (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (

ex102amendedandrestatede 1 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025 (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (the “Company”) and Kristen K. Buck, M.D. (the “Executive”) of 727 Creek Road, Warminster, PA 18974. WITNESSETH: WHEREAS, the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizat

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | August 7, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This prese

a992lstacorporatepresent © L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | August 7, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbo

Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025, (the “Effective Date”) is by and between Lisata Therape

ex101amendedandrestatede Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025, (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (the “Company”) and David J. Mazzo, Ph.D. (the “Executive”). WITNESSETH: WHEREAS, the Company desires to continue

UNITED STATES PATENT AND TRADEMARK OFFICE APPLICA TTON NO. ISSUE DATE 19/023,048 08-Jul-2025 EGRANT NOTIFICATION UNffW STATES DEfARTMENT OF COMMERCE Ualted States Patent and Trademark Office Addres$:COMMISSIONER FOR PATENTS P.O. Box 1450 AJCXIDdria,

ex992patent UNITED STATES PATENT AND TRADEMARK OFFICE APPLICA TTON NO. ISSUE DATE 19/023,048 08-Jul-2025 EGRANT NOTIFICATION UNffW STATES DEfARTMENT OF COMMERCE Ualted States Patent and Trademark Office Addres$:COMMISSIONER FOR PATENTS P.O. Box 1450 AJCXIDdria, Virpnia 2231>14-S0 www.u,pto.gov PATENT NO. 12351653 Your electronic patent grant (eGrant) is now available, which can be accessed via Pat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 15, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 15, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent co

Exhibit 99.1 Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING RIDGE, N.J. (July 15, 2025) – Lisata Therapeutics, Inc. (Nasdaq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 26, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 26, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | June 26, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presen

ex992lstacorporatepresen © L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | June 26, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor

EXHIBIT 99.1 Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer ASCEND comprises two dosin

EXHIBIT 99.1 Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective respon

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | June 17, 2025 Nasdaq: LSTA David J. Mazzo, Ph.D. President and Chief Executive Officer Ex

exhibit991 © L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | June 17, 2025 Nasdaq: LSTA David J. Mazzo, Ph.D. President and Chief Executive Officer Exhibit 99.1 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 17, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 17, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

1 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025 (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (

ex102amendedandrestatede 1 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025 (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (the “Company”) and Kristen K. Buck, M.D. (the “Executive”) of 727 Creek Road, Warminster, PA 18974. WITNESSETH: WHEREAS, the

Exhibit 10.4 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and Tariq Imam (“Executive”). WITNESSETH WHER

ex104arseparationbenefit Exhibit 10.4 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and Tariq Imam (“Executive”). WITNESSETH WHEREAS, the Company and Executive previously entered into the Prior Agreements (as defined in Section 1(f) below); and WHEREAS t

Exhibit 10.3 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and James Nisco (“Executive”). WITNESSETH WHE

ex103arseparationbenefit Exhibit 10.3 AMENDED AND RESTATED SEPARATION BENEFITS AGREEMENT This SEPARATION BENEFITS AGREEMENT (this “Agreement”), dated as of June 10, 2025, is by and between Lisata Therapeutics Inc. (the “Company”) and James Nisco (“Executive”). WITNESSETH WHEREAS, the Company and Executive previously entered into the Prior Agreements (as defined in Section 1(f) below); and WHEREAS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 10, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025, (the “Effective Date”) is by and between Lisata Therape

ex101amendedandrestatede Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of June 10, 2025, and effective on June 10, 2025, (the “Effective Date”) is by and between Lisata Therapeutics, Inc. (the “Company”) and David J. Mazzo, Ph.D. (the “Executive”). WITNESSETH: WHEREAS, the Company desires to continue

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 10, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS,

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentati

Exhibit 99.1 Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call scheduled for today at 4:30 p.m. Eas

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | May 8, 2025 Nasdaq: LSTA Exhibit 99.2Exhibit 99.2 2 Forward-looking statements advisory T

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | May 8, 2025 Nasdaq: LSTA Exhibit 99.2Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by th

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 8, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months Enrollment completed in Q

Exhibit 99.1 Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months Enrollment completed in Qilu’s Phase 2 trial evaluating certepetide for the treatment of first-line mPDAC Advancing development portfolio with multiple milestones

CALADRIUS BIOSCIENCES, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (formerly the NeoStem, Inc. 2012 Employee Stock Purchase Plan) 1. Purpose. The purpose of the Caladrius Biosciences, Inc. 2017 Employee Stock Purchase Plan (the “Plan”) is to amend and res

CALADRIUS BIOSCIENCES, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (formerly the NeoStem, Inc. 2012 Employee Stock Purchase Plan) 1. Purpose. The purpose of the Caladrius Biosciences, Inc. 2017 Employee Stock Purchase Plan (the “Plan”) is to amend and restate the NeoStem, Inc. 2012 Employee Stock Purchase Plan in order to further promote the interest of Caladrius Biosciences, Inc., a Delaware corporati

A-1 EXHIBIT 10.2 CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN _____________________________ Effective as of June 20, 2018 _____________________________ 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2

A-1 EXHIBIT 10.2 CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN Effective as of June 20, 2018 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan (the “Plan”) are: to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to Employees, Directors

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | February 27, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This pr

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | February 27, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Priv

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 27, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organi

Subsidiaries of Lisata Therapeutics, Inc. Entity (1) Percentage of Ownership Location Athelos Corporation (2) 99% United States of America Lisata Therapeutics Australia Pty Ltd 100% Australia Lisata Therapeutics Ireland Limited 100% Ireland Lisata Th

Exhibit 21.1 Subsidiaries of Lisata Therapeutics, Inc. Entity (1) Percentage of Ownership Location Athelos Corporation (2) 99% United States of America Lisata Therapeutics Australia Pty Ltd 100% Australia Lisata Therapeutics Ireland Limited 100% Ireland Lisata Therapeutics KK 100% Japan Lisata Therapeutics (U.K.) Limited 100% United Kingdom (1) Subsidiaries listed are as of the Company's filing da

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEU

Exhibit 10.14 David J. Mazzo, PhD President & CEO Mark Land CEO David J. Mazzo, PhD President & CEO Mark Land CEO

Exhibit 10.14 David J. Mazzo, PhD President & CEO Mark Land CEO David J. Mazzo, PhD President & CEO Mark Land CEO

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 22, 2025 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | January 22, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This pre

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | January 22, 2025 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Priva

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma Cohort A data to be presented in a post

Exhibit 99.1 Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall s

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 3, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m

Exhibit 99.1 Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (November 12, 2024) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 12, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organi

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation | November 12, 2024 Nasdaq: LST

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation | November 12, 2024 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTI

Up to $9,855,890 Common Stock

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-279034 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2024)   Up to $9,855,890 Common Stock We entered into an At The Market Offering Agreement (the “sales agreement”), dated June 4, 2021, with H.C. Wainwright & Co., LLC (“Wainwright”), relating to shares of our common stock, $0.001 par value per share, offered by this pros

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 12, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS, I

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation | August 12, 2024 Nasdaq: LSTA

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation | August 12, 2024 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertai

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into earl

Exhibit 99.1 Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, NJ (August 12,

Calculation of Filing Fee Table Form S-8 (Form Type) Lisata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Lisata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on July 15, 2024

As filed with the Securities and Exchange Commission on July 15, 2024 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 27, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation| May 9, 2024 Nasdaq: LSTA Exhib

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer www.lisata.com Corporate Presentation| May 9, 2024 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS,

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering

Exhibit 99.1 Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, NJ (May 9, 2024) – Lisata Therapeut

LISATA THERAPEUTICS, INC. 110 Allen Road, Second Floor Basking Ridge, NJ 07920 May 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Lisata T

LISATA THERAPEUTICS, INC. 110 Allen Road, Second Floor Basking Ridge, NJ 07920 May 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Lisata Therapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2024 File No. 333-279034 (the “Registration Statement”) Acceleration Request Ladies

As filed with the Securities and Exchange Commission on May 1, 2024

As filed with the Securities and Exchange Commission on May 1, 2024 Registration No.

Calculation of Filing Fee Table Form S-3 (Form Type) Lisata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Lisata Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 15, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 15, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizat

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Co

Exhibit 99.1 Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (February 29, 2024) – Lisata Therapeutics, Inc. (Nasdaq: LS

A-1 EXHIBIT 10.2 CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN _____________________________ Effective as of June 20, 2018 _____________________________ 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2

A-1 EXHIBIT 10.2 CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN Effective as of June 20, 2018 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan (the “Plan”) are: to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to Employees, Directors

EXHIBIT 97 LISATA THERAPEUTICS, INC. INCENTIVE RECOUPMENT POLICY I. Introduction The Board of Directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create

EXHIBIT 97 LISATA THERAPEUTICS, INC. INCENTIVE RECOUPMENT POLICY I. Introduction The Board of Directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Th

CALADRIUS BIOSCIENCES, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (formerly the NeoStem, Inc. 2012 Employee Stock Purchase Plan) 1. Purpose. The purpose of the Caladrius Biosciences, Inc. 2017 Employee Stock Purchase Plan (the “Plan”) is to amend and res

CALADRIUS BIOSCIENCES, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (formerly the NeoStem, Inc. 2012 Employee Stock Purchase Plan) 1. Purpose. The purpose of the Caladrius Biosciences, Inc. 2017 Employee Stock Purchase Plan (the “Plan”) is to amend and restate the NeoStem, Inc. 2012 Employee Stock Purchase Plan in order to further promote the interest of Caladrius Biosciences, Inc., a Delaware corporati

F2827/1 10/30/15 1778477.01 LISATA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Tradi

F2827/1 10/30/15 1778477.01 LISATA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures are being provided to you. You should read this Policy, address questions to Todd Girolamo, General Counsel of Lisata Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEU

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | February 29, 2024 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This pr

© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 4 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | February 29, 2024 Nasdaq: LSTA Exhibit 99.2 2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Priv

Subsidiaries of Lisata Therapeutics, Inc. Entity (1) Percentage of Ownership Location Athelos Corporation (2) 99% United States of America Lisata Therapeutics Australia Pty Ltd 100% Australia Lisata Therapeutics Ireland Limited 100% Ireland Lisata Th

Exhibit 21.1 Subsidiaries of Lisata Therapeutics, Inc. Entity (1) Percentage of Ownership Location Athelos Corporation (2) 99% United States of America Lisata Therapeutics Australia Pty Ltd 100% Australia Lisata Therapeutics Ireland Limited 100% Ireland Lisata Therapeutics KK 100% Japan Lisata Therapeutics (U.K.) Limited 100% United Kingdom (1) Subsidiaries listed are as of the Company's filing da

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 29, 2024 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organi

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 2, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued ra

EX-99.1 2 ex991earningsrelease3q23.htm EX-99.1 Exhibit 99.1 Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND Orphan drug designations granted for LSTA1 in malignant glioma (U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTI

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered Corporate Presentation | November 2, 2023 Nasdaq: LSTA www.lisata.com Exhibit 99.2 Forward-looking statements adv

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered Corporate Presentation | November 2, 2023 Nasdaq: LSTA www.lisata.com Exhibit 99.2 Forward-looking statements advisory This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provide

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology

Exhibit 99.1 Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology transfer agreement executed for Company’s tumor penetrating nanocomplex (TPN) platform Company to host conference call Tuesday, August 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS, I

1 SEVERANCE AGREEMENT May 1, 2023 PERSONAL AND CONFIDENTIAL BY EMAIL David Slack Dear David: The purpose of this Severance Agreement (the “Agreement”) is to set forth the terms of your separation from Lisata Therapeutics Inc. (the “Company”). Payment

ex101slackseveranceagm05 1 SEVERANCE AGREEMENT May 1, 2023 PERSONAL AND CONFIDENTIAL BY EMAIL David Slack Dear David: The purpose of this Severance Agreement (the “Agreement”) is to set forth the terms of your separation from Lisata Therapeutics Inc.

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. President and Chief Executive Officer Corporate Presentation | August 14, 2023 Nasdaq: LSTA

lisatacorporatepresentat C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c .

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 14, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiza

Calculation of Filing Fee Table Form S-8 (Form Type) Lisata Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Lisata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on July 13, 2023

As filed with the Securities and Exchange Commission on July 13, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 11, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 11, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company

Exhibit 99.1 Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING RIDGE, NJ (July 11, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 14, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 14, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer Corporate Presentation | May 9, 2023 Nasdaq: LSTA www.lisata.com Ex

ex992lisatacorporatepres C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organization

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time

Exhibit 99.1 Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (May 9, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 1, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 1, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organization

LISATA THERAPEUTICS, INC. CLAWBACK POLICY

LISATA THERAPEUTICS, INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore a

A-1 CALADRIUS BIOSCIENCES, INC. 2015 EQUITY COMPENSATION PLAN _________________________ Effective as of July 15, 2015 _________________________ 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2015 Equity Compensation Plan, s

ex104-2015equitycompensa A-1 CALADRIUS BIOSCIENCES, INC. 2015 EQUITY COMPENSATION PLAN Effective as of July 15, 2015 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2015 Equity Compensation Plan, subject to shareholder approval at the 2015 annual meeting of shareholders on July 14, 2015 (the “Plan”) are: to attract and retain the best available personnel for positions of

CODE OF ETHICS FOR SENIOR FINANCIAL OFFICERS

Exhibit 14.1 CODE OF ETHICS FOR SENIOR FINANCIAL OFFICERS I. PURPOSE The Board of Directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) has adopted the following Code of Ethics (the “Code”) to apply to the Company’s Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Controller, and any persons performing similar functions (collectively, the “Senior Financi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 30, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 30, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizat

A-1 APPENDIX A CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN _____________________________ Effective as of June 20, 2018 _____________________________ 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 201

ex1032018equityincentive A-1 APPENDIX A CALADRIUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN Effective as of June 20, 2018 1. Purposes of the Plan. The purposes of this Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan (the “Plan”) are: to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives t

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer Corporate Presentation | March 30, 2023 Nasdaq: LSTA www.lisata.com

a992lisatacorporateprese C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c .

Amended and Restated Board of Directors Compensation Policy

Exhibit 10.1 Amended and Restated Board of Directors Compensation Policy On April 21, 2021 the Board of Directors of Lisata Therapeutics, Inc. (the "Company") adopted the Amended and Restated Board of Directors Compensation Policy (the "Board of Directors Compensation Policy") for all non-employee Board members, providing that: •each Board member shall be authorized to receive an annual cash compe

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time

Exhibit 99.1 Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (March 30, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEU

Subsidiaries of Lisata Therapeutics, Inc. Entity Percentage of Ownership Location Amorcyte, LLC 100% United States of America Athelos Corporation (1) 99% United States of America Cend Therapeutics, Inc. 100% United States of America NeoStem Oncology,

Exhibit 21.1 Subsidiaries of Lisata Therapeutics, Inc. Entity Percentage of Ownership Location Amorcyte, LLC 100% United States of America Athelos Corporation (1) 99% United States of America Cend Therapeutics, Inc. 100% United States of America NeoStem Oncology, LLC 100% United States of America Lisata Therapeutics Australia Pty Ltd 100% Australia Lisata Therapeutics Ireland Limited 100% Ireland

AMENDED AND RESTATED NEOSTEM, INC. 2009 EQUITY COMPENSATION PLAN 1. Purposes of the Plan. The purposes of this Amended and Restated NeoStem, Inc. 2009 Equity Compensation Plan (as amended and restated as of October 5, 2012), subject to stockholder ap

ex105-amendedrestated200 AMENDED AND RESTATED NEOSTEM, INC. 2009 EQUITY COMPENSATION PLAN 1. Purposes of the Plan. The purposes of this Amended and Restated NeoStem, Inc. 2009 Equity Compensation Plan (as amended and restated as of October 5, 2012), subject to stockholder approval at the 2012 annual meeting of stockholders on October 5, 2012 (the “Plan”) are: to attract and retain the best availab

1 LISATA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN, AS AMENDED Effective as of September 15, 2022 1. Purposes of the Plan. The purposes of this Lisata Therapeutics, Inc. (f/k/a Caladrius Biosciences, Inc.) 2018 Equity Incentive Compe

ex102-lisatatherapeutics 1 LISATA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE COMPENSATION PLAN, AS AMENDED Effective as of September 15, 2022 1. Purposes of the Plan. The purposes of this Lisata Therapeutics, Inc. (f/k/a Caladrius Biosciences, Inc.) 2018 Equity Incentive Compensation Plan (the “Plan”) are: to attract and retain the best available personnel for positions of substantial responsibility

C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . LISATA EUTICSTHERAP Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer Corporate Presentation | February 6, 2023 Nasda

lisatacorporatepresentat C o p y r i g h t © 2 0 2 3 L i s a t a T h e r a p e u t i c s , I n c .

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 6, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exac

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 6, 2023 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organization) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 LISATA THERAPEUTI

Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time

Exhibit 99.1 Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time •Post-merger profile describes rich clinical development pipeline backed by solid financial situation •Qilu Pharmaceutical Phase 1b/2 study of LSTA1 in China ongoing; Preliminary data expected in the second half of 2023 •Phase 2b s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 10, 2022 Date of Report (date of earliest event reported) LISATA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 10, 2022 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organi

C o p y r i g h t © 2 0 2 2 L i s a t a T h e r a p e u t i c s , I n c . A l l r i g h t s r e s e r v e d . LISATA EUTICSTHERAP Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer Corporate Presentation | November 10, 2022 Nasd

ex992corporatedec5p11092 C o p y r i g h t © 2 0 2 2 L i s a t a T h e r a p e u t i c s , I n c .

Cend 2016 Equity Incentive Plan, including all amendments thereto

Exhibit 99.1 2016 EQUITY INCENTIVE PLAN OF DRUGCENDR, INC. Adopted September 14, 2016 TABLE OF CONTENTS Page 1. GENERAL 1 2. DEFINITIONS 1 3. ADMINISTRATION 5 4. SHARES SUBJECT TO THE PLAN 7 5. ELIGIBILITY 8 6. OPTION AGREEMENT PROVISIONS 8 7. PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS 12 8. COVENANTS OF THE COMPANY 13 9. USE OF PROCEEDS 13 10. ADJUSTMENTS UPON CHANGE IN COMMON STOCK 13 11. ADJ

Calculation of Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Lisata Therapeutics, Inc.

As filed with the Securities and Exchange Commission on [•], 2022

As filed with the Securities and Exchange Commission on [•], 2022 Registration No.

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 LISATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33650 22-2343568 (State or Other Jurisdiction of Incorpo

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On April 26, 2022, Caladrius Biosciences, Inc. (?Caladrius?), CS Cedar Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Caladrius (?Merger Sub?), and Cend Therapeutics, Inc. (?Cend? or the ?Company?), a privately-held, clinical-stage biotechnology company, entered into an Agreement and Plan of Merger an

CEND THERAPEUTICS, INC. INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Exhibit 99.3 CEND THERAPEUTICS, INC. INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of December 31, 2021 and June 30, 2022 (unaudited).. F-3 Condensed Consolidated Statements of Operations for the Six Months Ended June 30, 2021 and 2022 (unaudited).. F-4 Condensed Consolidated Statements of Comprehensive Income (Loss) for the Six Months Ende

Financial Statements and Exhibits, Other Events

false0000320017NJNASDAQ00003200172022-09-142022-09-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CEND BUSINESS

Exhibit 99.1 CEND BUSINESS Overview Cend Therapeutics, Inc. (formerly DrugCendR, Inc.) is a Delaware corporation, formed in October 2015 (?Cend? or ?the Company?) and based in San Diego, California. Cend is focused on a tumor microenvironment (?TME?)-modifying approach to enable more effective treatment for a range of solid tumor cancers. Cend is advancing a pipeline of product and partnering oppo

Risks Related to Cend

Exhibit 99.2 Risks Related to Cend Risks Related to Cend?s Business Cend has incurred net losses for all but one year since inception and anticipates that it will continue to incur losses for the foreseeable future and may never achieve or maintain profitability. Cend is a development-stage drug discovery and development company with a limited operating history, and, with the exception of the year

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 29, 2022 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organ

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254971 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 4, 2021 and the Prospectus Supplement, dated June 4, 2021) $17,698,943 Common Stock This prospectus supplement amends and supplements the information in our prospectus dated May 4, 2021, which was included in our Registration Statement on Form S-3 (File No. 333-254971), and our prospectu

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 22, 2022 Date of Report (date of earliest event reported) LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organ

Targeted Therapy Delivered S e p te mb e r 2 2 , 2 0 22 | N a s d a q : L STA | w w w. l i s a ta . co m David J. Mazzo, Ph.D., Chief Executive Officer Exhibit 99.1 Forward-looking Statements This presentation contains “forward-looking statements” th

a991lisatacorporateprese Targeted Therapy Delivered S e p te mb e r 2 2 , 2 0 22 | N a s d a q : L STA | w w w.

Certificate of Amendment to Amended and Restated Certificate of Incorporation

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALADRIUS BIOSCIENCES, INC. Caladrius Biosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, as amended (the ?DGCL?), hereby certifies as follows: A. The name of the Corporation is Caladrius Biosciences, I

CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CALADRIUS BIOSCIENCES, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALADRIUS BIOSCIENCES, INC. Caladrius Biosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, as amended (the ?DGCL?), hereby certifies as follows: A. The name of the Corporation is Caladrius Biosciences, I

EMPLOYMENT AGREEMENT

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this "Agreement"), dated as of September 15, 2022 (the "Execution Date") is by and between Lisata Therapeutics (the "Company") and David Slack (the "Executive") WITNESSETH: WHEREAS, the Company desires to employ the Executive as its President, and Chief Business Officer and the Executive desires to be so employed by the Company; and WHER

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 LISATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33650 22-2343568 (State or Other Jurisdiction of Incorporation) (Commissio

Targeted Therapy Delivered September 15, 2022 | Nasdaq: LSTA | www.lisata.com David J. Mazzo, Ph.D., Chief Executive Officer Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncerta

Exhibit 99.2 Targeted Therapy Delivered September 15, 2022 | Nasdaq: LSTA | www.lisata.com David J. Mazzo, Ph.D., Chief Executive Officer Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than state

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and inves

Exhibit 99.1 Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceut

LISATA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT

Exhibit 10.2 LISATA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of September 15, 2022 by and between Lisata Therapeutics, Inc., a Delaware corporation (the "Company"), and [ ]("Indemnitee"). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other capacitie

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 13, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or org

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders

Exhibit 99.1 Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, NJ (September 14, 2022) ? Caladrius Biosciences, Inc. (Nasdaq: CLBS) (?Caladrius? or the ?Company?), announced today that, based upon the final vote count certified by the independent inspector of elections

Certificate of Amendment to Amended and Restated Certificate of Incorporation

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALADRIUS BIOSCIENCES, INC. Caladrius Biosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, as amended (the ?DGCL?), hereby certifies as follows: A. The name of the Corporation is Caladrius Biosciences, I

Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-

Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-33650 Dear Caladrius Shareholder: YOUR PARTICIPATION IS IMPORTANT ? PLEASE VOTE TODAY! According to our latest records, your proxy vote relating to th

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 18, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organi

David J. Mazzo, PhD President & Chief Executive Of f icer Au g u s t 15 , 2 0 2 2 | N a s da q : CL B S The Evolution of into Hello. This is David Mazzo, President and CEO of Caladrius Biosciences here to provide you with a summary of the information

425 1 clbspresentations-4xfin.htm 425 David J. Mazzo, PhD President & Chief Executive Of f icer Au g u s t 15 , 2 0 2 2 | N a s da q : CL B S The Evolution of into Hello. This is David Mazzo, President and CEO of Caladrius Biosciences here to provide you with a summary of the information from the proxy statement/prospectus recently sent to shareholders detailing the proposed merger of Caladrius wi

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer Study to be part of Roche’s Morpheus Platform designed

Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-33650 Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combina

Caladrius Biosciences Inc. (Q2 2022 Results)

Exhibit 99.2 Caladrius Biosciences Inc. (Q2 2022 Results) August 04, 2022 Corporate Speakers: ?John Menditto; Caladrius Biosciences, Inc.; VP of IR & Corporate Communications ?David Mazzo; Caladrius Biosciences, Inc.; President, CEO ?James Nisco; Caladrius Biosciences, Inc.; VP of Finance & Treasury ?Kristen Buck; Caladrius Biosciences, Inc.; Executive VP of R&D and Chief Medical Officer Participa

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisa

Exhibit 99.1 Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 4, 2022) ? Caladrius Biosciences, Inc.

David J. Mazzo, PhD President & Chief Executive Of ficer Au g u s t 4 , 2 0 2 2| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.3 Forward-Looking Statements This presentation contains “forward-looking s

ex99 David J. Mazzo, PhD President & Chief Executive Of ficer Au g u s t 4 , 2 0 2 2| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.3 Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 4, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSCIENCES,

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-265638 ? ? ? ? PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Caladrius Biosciences, Inc. and Cend Therapeutics, Inc.: Caladrius Biosciences, Inc. (?Caladrius?) and Cend Therapeutics, Inc. (?Cend?) have entered into an Agreement and Plan of Merger and Reorganization (the ?Merger Agreement?) pursuant to whic

EX-99.1

Exhibit 99.1

As filed with the Securities and Exchange Commission on July 26, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 26, 2022 Registration No.

Caladrius Biosciences, Inc. 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920

Caladrius Biosciences, Inc. 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 July 26, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Caladrius Biosciences, Inc. Registration Statement on Form S-4 File No. 333-265638 Request for Acceleration of Effectiveness Ladies and Gentlemen: In accordance wi

CONSENT OF MOHAMMAD AZAB

Exhibit 99.8 CONSENT OF MOHAMMAD AZAB Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Caladrius Biosciences, Inc., a Delaware corporation (the ?Company?), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to ser

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates f

Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-33650 Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology P

SECOND AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AND DRUGCENDR, LLC

Exhibit 10.20 SECOND AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AND DRUGCENDR, LLC This SECOND AMENDMENT to the AGREEMENT defined below, is effective as of the last date of the last authorized signature affixed hereto, is by and between Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit, public benefit corporation, hav

FIRST AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DRUGCENDR, LLC

Exhibit 10.19 FIRST AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AND DRUGCENDR, LLC This First Amendment (?First Amendment?), effective as of the last date of the last authorized signature affixed hereto, is by and between Sanford Burnham Prebys Medical Discovery Institute (?SBP?, as defined in the Agreement) and DrugCendR, LLC (?Licensee?) who here

CONSENT OF HEIDI HENSON

Exhibit 99.6 CONSENT OF HEIDI HENSON Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Caladrius Biosciences, Inc., a Delaware corporation (the ?Company?), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to serv

As filed with the Securities and Exchange Commission on June 15, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 15, 2022 Registration No.

CONSENT OF ERKKI RUOSLAHTI

Exhibit 99.7 CONSENT OF ERKKI RUOSLAHTI Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Caladrius Biosciences, Inc., a Delaware corporation (the ?Company?), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to s

AMENDMENT TO EMPLOYMENT AGREEMENT

Exhibit 10.7(B) AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment ("Amendment"), dated as of January 16, 2015 (the "Amendment Date"), amends the Employment Agreement between NeoStem, Inc. (the "Company") and David J. Mazzo, Ph.D. (the "Executive") dated as of January 5, 2015 (the "Agreement"). All capitalized terms not defined herein shall have the meanings set forth in the Agreement. RECITALS WHER

EMPLOYMENT AGREEMENT

Exhibit 10.22 EMPLOYMENT AGREEMENT THIS Employment Agreement (hereinafter ?Agreement?) is entered into and becomes effective as of March 29 2021 by and between Cend Therapeutics, Inc. (hereinafter ?CEND? or ?Employer?), and David Slack (hereinafter ?Employee?). RECITALS A. CEND is a corporation and is doing business in the State of California. B. Both CEND and Employee desire that Employee be hire

CONSENT OF BACK BAY LIFE SCIENCES ADVISORS, LLC

Exhibit 99.3 CONSENT OF BACK BAY LIFE SCIENCES ADVISORS, LLC We hereby consent to (i) the inclusion of our opinion letter, dated April 25, 2022, to the Board of Directors of Caladrius Biosciences, Inc. (?Caladrius?), as an Annex to the joint proxy statement/prospectus that forms a part of the Registration Statement on Form S-4 of Caladrius, as filed by Caladrius on June 15, 2022 (the ?Registration

CONSENT OF DAVID SLACK

Exhibit 99.5 CONSENT OF DAVID SLACK Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Caladrius Biosciences, Inc., a Delaware corporation (the ?Company?), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to serve

THIRD AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AND CEND THERAPEUTICS, INC.

Exhibit 10.21 THIRD AMENDMENT TO THE EXCLUSIVE LICENSE BETWEEN SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AND CEND THERAPEUTICS, INC. This THIRD AMENDMENT to the AGREEMENT defined below, is effective as of the last date of the last authorized signature affixed hereto, is by and between Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit, public benefit corporati

EXCLUSIVE LICENSE AGREEMENT DrugCendR, LLC Sanford Burnham Prebys Medical Discovery Institute

Exhibit 10.18 EXCLUSIVE LICENSE AGREEMENT between DrugCendR, LLC and Sanford Burnham Prebys Medical Discovery Institute This Exclusive License Agreement (?Agreement?), is entered into as of the 1st day of December, 2015 (hereinafter ?Effective Date?), by and between Sanford Burnham Prebys Medical Discovery Institute (the ?SBP?), a California 501(c)(3) corporation, having an address at 10901 North

Calculation of Filing Fee Tables FORM S-4 (Form Type) CALADRIUS BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables FORM S-4 (Form Type) CALADRIUS BIOSCIENCES, INC.

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

425 1 a425businesscombinationpre.htm 425 Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-33650 Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2

David J. Mazzo, PhD President & Chief Executive Of ficer M ay 2 3 , 2 0 2 2|Na s d aq : C L B S Developing Innovative Therapies to Treat or Reverse Disease Exhibit 99.2 Forward-Looking Statements This presentation contains “forward-looking statements

David J. Mazzo, PhD President & Chief Executive Of ficer M ay 2 3 , 2 0 2 2|Na s d aq : C L B S Developing Innovative Therapies to Treat or Reverse Disease Exhibit 99.2 Forward-Looking Statements This presentation contains ?forward-looking statements? that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. A

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next d

Exhibit 99.1 Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA? in Coronary Microvascular Dysfunction Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA? to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a co

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 23, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSCIENCES

David J. Mazzo, PhD President & Chief Executive Of ficer M ay 5 , 2 0 22| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 Forward-Looking Statements This presentation contains “forward-looking statemen

David J. Mazzo, PhD President & Chief Executive Of ficer M ay 5 , 2 0 22| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 5, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organizati

Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position

Exhibit 99.1 Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development portfolio Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (May 5, 20

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 26, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

Caladrius and Cend Therapeutics Definitive Merger Agreement Apri l 27, 2022 Proposed combination to create L isata Therapeut ics , a new diversif ied therapeutics company with a robust development pipel ine Exhibit 99.2 Forward-Looking Statements Thi

Caladrius and Cend Therapeutics Definitive Merger Agreement Apri l 27, 2022 Proposed combination to create L isata Therapeut ics , a new diversif ied therapeutics company with a robust development pipel ine Exhibit 99.

1

425 1 form42520220427.htm 425 Filed by Caladrius Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12 Of the Securities Exchange Act of 1934, as amended Subject Company: Caladrius Biosciences, Inc. Commission File No.: 001-33650 On April 27, 2022, Caladrius Biosciences, Inc. (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) hosted an inv

1 EXHIBIT 10.1 SERIES D PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES D PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 26th day of April, 2022 by and between CEND Therapeutics, Inc., a Delaware corporation (the “Company”) a

1 EXHIBIT 10.1 SERIES D PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES D PREFERRED STOCK PURCHASE AGREEMENT (this ?Agreement?), is made as of the 26th day of April, 2022 by and between CEND Therapeutics, Inc., a Delaware corporation (the ?Company?) and Caladrius Biosciences, Inc. (the ?Purchaser?). Substantially simultaneously with the execution of this Agreement, the Company, Purchaser and CS Ced

Execution Version EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: CALADRIUS BIOSCIENCES, INC., a Delaware corporation; CS CEDAR MERGER SUB, INC., a Delaware corporation; and CEND THERAPEUTICS, INC., a Delaware corporation Dated as

EX-2.1 2 ex21-mergeragreement10pf.htm EX-2.1 Execution Version EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: CALADRIUS BIOSCIENCES, INC., a Delaware corporation; CS CEDAR MERGER SUB, INC., a Delaware corporation; and CEND THERAPEUTICS, INC., a Delaware corporation Dated as of April 26, 2022 i TABLE OF CONTENTS Page Section 1 Description of Transaction .........................

EXHIBIT 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT This COMPANY STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”), dated as of April 26, 2022, is by and between Caladrius Biosciences, Inc., a Delaware corporation (“Caladrius”), and the Person s

EX-2.2 3 exhibit22-supportagreeme.htm EX-2.2 EXHIBIT 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT This COMPANY STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”), dated as of April 26, 2022, is by and between Caladrius Biosciences, Inc., a Delaware corporation (“Caladrius”), and the Person set forth on Schedule A (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder

- 1 - Error! Unknown document property name. EXHIBIT 10.2 Collaboration Agreement This Collaboration Agreement (“Agreement”) is entered into on April 26, 2022 (“Effective Date”) between Caladrius Biosciences, Inc., having an address at 110 Allen Road

- 1 - Error! Unknown document property name. EXHIBIT 10.2 Collaboration Agreement This Collaboration Agreement (?Agreement?) is entered into on April 26, 2022 (?Effective Date?) between Caladrius Biosciences, Inc., having an address at 110 Allen Road, Suite 2, Basking Ridge, NJ 07920 (?Caladrius?) and Cend Therapeutics, Inc., having an address at 12544 High Bluff Drive, Suite 400, San Diego, CA 92

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product deve

Exhibit 99.1 Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combine development pipelines f

EXHIBIT 2.4 FORM OF LOCK-UP AGREEMENT April 26, 2022 [●] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Caladrius Biosciences, Inc., a Delaware corporation (“Caladrius”) proposes

EX-2.4 5 exhibit24-lockxupagreeme.htm EX-2.4 EXHIBIT 2.4 FORM OF LOCK-UP AGREEMENT April 26, 2022 [●] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Caladrius Biosciences, Inc., a Delaware corporation (“Caladrius”) proposes to enter into an Agreement and Plan of Merger and Reorganization (as the same may be amended from time to

EXHIBIT 2.3 FORM OF CALADRIUS STOCKHOLDER SUPPORT AGREEMENT This CALADRIUS STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”), dated April 26, 2022, is by and between Cend Therapeutics, Inc., a Delaware corporation (the “Company”), and the Person set f

EXHIBIT 2.3 FORM OF CALADRIUS STOCKHOLDER SUPPORT AGREEMENT This CALADRIUS STOCKHOLDER SUPPORT AGREEMENT (this ?Agreement?), dated April 26, 2022, is by and between Cend Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Person set forth on Schedule A (the ?Stockholder?). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par val

CODE OF ETHICS FOR SENIOR FINANCIAL OFFICERS I. PURPOSE The Board of Directors (the "Board") of Caladrius Biosciences, Inc. (the "Company") has adopted the following Code of Ethics (the "Code") to apply to the Company's Chief Executive Officer, Chief

EX-14.1 3 ex141codeofconductandeth.htm EX-14.1 CODE OF ETHICS FOR SENIOR FINANCIAL OFFICERS I. PURPOSE The Board of Directors (the "Board") of Caladrius Biosciences, Inc. (the "Company") has adopted the following Code of Ethics (the "Code") to apply to the Company's Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Controller, or persons performing similar functions (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-3

EXHIBIT 10.19

EX-10.19 2 ex1019buckemploymentcont.htm EX-10.19 EXHIBIT 10.19

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 22, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSC

David J. Mazzo, PhD President & Chief Executive Of ficer M a rc h 2 2 , 2 0 22| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 This Investor Presentation contains forward-looking statements within the

EX-99.2 3 ex992corppresentationma.htm EX-99.2 David J. Mazzo, PhD President & Chief Executive Of ficer M a rc h 2 2 , 2 0 22| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect man

Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern time

Exhibit 99.1 Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2022) ? Caladrius Biosciences, Inc. (Nasdaq: CLBS) (?Caladrius? or the ?Company?), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 24, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or orga

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 18, 2022 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or orga

CLBS / Caladrius Biosciences Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 128058203 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Caladrius Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 128058203 (CUSIP

CLBS / Caladrius Biosciences Inc / MMCAP International Inc. SPC - FORM SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G AMENDMENT NO.

CLBS / Caladrius Biosciences Inc / Empery Asset Management, LP - CALADRIUS BIOSCIENCES, INC. Passive Investment

SC 13G/A 1 p22-0154sc13ga.htm CALADRIUS BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Caladrius Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 128058203 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Chec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSCIE

David J. Mazzo, PhD President & Chief Executive Of ficer N ove m b er 4 , 2 0 21| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 This Investor Presentation contains forward-looking statements within t

David J. Mazzo, PhD President & Chief Executive Of ficer N ove m b er 4 , 2 0 21| N a s d a q : C L B S Developing Innovative Therapies that Treat or Reverse Disease Exhibit 99.2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management?s current expectations, as of the da

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2021 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organ

Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:3

Exhibit 99.1 Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 4, 2021) ? Caladrius Biosciences, Inc. (Nasdaq: CLBS) (?Caladrius? or the ?Company?), a

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 5, 2021 Date of Report (date of earliest event reported) CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-33650 22-2343568 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSCIENCES,

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease Au g u s t 5 , 2 0 21| N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements within th

EX-99.2 3 ex992clbscorppresentatio.htm EX-99.2 David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease Au g u s t 5 , 2 0 21| N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect m

Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern Time

Exhibit 99.1 Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (August 5, 2021) ? Caladrius Biosciences, Inc. (Nasdaq: CLBS) (?Caladrius? or the ?Company?), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease

As filed with the Securities and Exchange Commission on June 30, 2021

As filed with the Securities and Exchange Commission on June 30, 2021 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Number)

Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT June 4, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Caladrius Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms i

EX-10.1 3 exhibit101atmagreementju.htm EX-10.1 Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT June 4, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Caladrius Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definiti

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Number)

Up to $50,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254971 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2021) Up to $50,000,000 Common Stock We have entered into an At The Market Offering Agreement (the "sales agreement"), dated June 4, 2021, with H.C. Wainwright & Co., LLC ("Wainwright"), relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplem

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease M ay 6 , 2 0 21 | N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements within the mea

EX-99.2 3 ex992clbscorppresentatio.htm EX-99.2 David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease M ay 6 , 2 0 21 | N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect manage

Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern Time

EX-99.1 2 ex991earningsrelease1q21.htm EX-99.1 Exhibit 99.1 Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (May 6, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cel

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Number) 2

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSCIENCES

$150,000,000 CALADRIUS BIOSCIENCES, INC. Common Stock Preferred Stock Debt Securities

Filed pursuant to Rule 424(b)(2) Registration No. 333-254971 PROSPECTUS $150,000,000 CALADRIUS BIOSCIENCES, INC. Common Stock Preferred Stock Debt Securities Warrants Units This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $150,000,000 of any combination of the securities described in this prospectus, ei

Caladrius Biosciences, Inc. 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 (908) 842-0100

Caladrius Biosciences, Inc. 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 (908) 842-0100 April 30, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz RE: Caladrius Biosciences, Inc. Registration Statement on Form S-3 File No. 333-254971 Acceleration Request Dear Ms. Schwartz: Wit

Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan, as amended, effective June 16, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

- DEFA 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stateme

- S-3

As filed with the Securities and Exchange Commission on April 1, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Number

1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement"), dated as of March 19, 2021 and effective on March 19, 2021, (the "Effective Date") is by and between Caladrius Biosciences, Inc. (the "Comp

EX-10.1 2 ex101to8-kcomplete.htm EX-10.1 1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement"), dated as of March 19, 2021 and effective on March 19, 2021, (the "Effective Date") is by and between Caladrius Biosciences, Inc. (the "Company") and David J. Mazzo, Ph.D. (the "Executive"). WITNESSETH: WHEREAS, the Company desires to continue to em

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-33650 CALADRIUS BIOSC

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Num

DESCRIPTION OF CAPITAL STOCK OF CALADRIUS BIOSCIENCES, INC.

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK OF CALADRIUS BIOSCIENCES, INC. The following is a summary of all material characteristics of our capital stock as set forth in our certificate of incorporation and bylaws, and our outstanding warrants. The summary does not purport to be complete and is qualified in its entirety by reference to our certificate of incorporation and bylaws, which are incorpora

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease Fe b r u a r y 2 5 , 2 0 21 | N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements wi

EX-99.2 3 ex992corporatedeck.htm EX-99.2 David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease Fe b r u a r y 2 5 , 2 0 21 | N a s d a q : C L B S Exhibit 99.2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect

Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference cal

EX-99.1 2 ex991earningsrelease4q20.htm EX-99.1 Exhibit 99.1 Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J. (February 25, 2021) – Caladrius Biosc

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Calad

CUSIP No: 128058203 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Caladrius Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 128058203 (CUSIP N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caladrius Biosciences, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caladrius Biosciences, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 128058203 (CUSIP Number) February 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Caladrius Biosciences Inc (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securiti

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Caladrius Biosciences Inc (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 128058203 (CUSIP Number) February 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

Caladrius Biosciences, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caladrius Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 128058203 (CUSIP Number) February 12, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

SC 13G/A 1 d880504713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Caladrius Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 128058203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the a

1,632,652 Shares of Common Stock Warrants to Purchase 816,326 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-226319 PROSPECTUS SUPPLEMENT (To Prospectus dated August 2, 2018) 1,632,652 Shares of Common Stock Warrants to Purchase 816,326 Shares of Common Stock We are offering 1,632,652 shares of our common stock, par value $0.001 per share (the “Common Stock”) and warrants to purchase up 816,326 shares of Common Stock, representing 50% of the shares of

SECURITIES PURCHASE AGREEMENT

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 12, 2021, between Caladrius Biosciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and con

24,906,134 Shares of Common Stock Warrants to Purchase 12,453,067 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-226319 PROSPECTUS SUPPLEMENT (To Prospectus dated August 2, 2018) 24,906,134 Shares of Common Stock Warrants to Purchase 12,453,067 Shares of Common Stock We are offering 24,906,134 shares of our common stock, par value $0.001 per share (the “Common Stock”) and warrants to purchase up 12,453,067 shares of Common Stock, representing 50% of the s

********************

EX-10.3 6 exhibit103hcw424b520210212.htm EX-10.3 Exhibit 10.3 Execution Version February 11, 2021 STRICTLY CONFIDENTIAL Caladrius Biosciences, Inc. 110 Allen Road, Second Floor Basking Ridge, NJ 07920 Attn: David J. Mazzo, Ph.D., President and Chief Executive Officer Dear Dr. Mazzo: This letter agreement (this “Agreement”) constitutes the agreement between Caladrius Biosciences, Inc. (the “Company

Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

EX-99.1 7 exhibit99120210211.htm EX-99.1 Exhibit 99.1 Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (February 12, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to rever

SECURITIES PURCHASE AGREEMENT

EX-10.1 4 exhibit10120210212.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 12, 2021, between Caladrius Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers

SERIES A COMMON STOCK PURCHASE WARRANT CALADRIUS BIOCIENCES, INC.

EX-4.1 2 exhibit4120210212.htm EX-4.1 Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT CALADRIUS BIOCIENCES, INC. Warrant Shares: Issue Date: February 17, 2021 Initial Exercise Date: February 17, 2021 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 a8-krdoffering20210212.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorpor

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-226319 SUPPLEMENT NO. 1 DATED FEBRUARY 12, 2021 TO PROSPECTUS SUPPLEMENT DATED MARCH 20, 2019 (To Prospectus dated August 2, 2018) Common Stock This Supplement No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated March 20, 2019 (the “Prospectus Supplement”). This Supplement should be read in

CALADRIUS BIOSCIENCES, INC. 18,750,000 Shares of Common Stock

Filed pursuant to Rule 424(b)(3) Registration No. 333-252560 PROSPECTUS CALADRIUS BIOSCIENCES, INC. 18,750,000 Shares of Common Stock The selling stockholders of Caladrius Biosciences, Inc. ("Caladrius," "we," "us" or the "Company") listed beginning on page 11 of this prospectus may offer and resell under this prospectus (i) up to 12,500,000 shares of our common stock and (ii) up to 6,250,000 shar

-

CORRESP 1 filename1.htm Caladrius Biosciences, Inc. 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 (908) 842-0100 February 3, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius RE: Caladrius Biosciences, Inc. Registration Statement on Form S-3 File No. 333-252560 Acceleration Request

- FORM S-3

As filed with the Securities and Exchange Commission on January 29, 2021 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Numb

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease J a n u a r y 2 9 , 2 0 21 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements wit

EX-99.1 2 ex991corporatedeckjanuar.htm EX-99.1 David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease J a n u a r y 2 9 , 2 0 21 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements ref

Securities Purchase Agreement, dated January 21, 2021, by and among the Company and the Investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on January 25, 2021).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 21, 2021, between Caladrius Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond

Caladrius Biosciences Announces $25.0 Million Private Placement

Exhibit 99.1 Caladrius Biosciences Announces $25.0 Million Private Placement BASKING RIDGE, N.J. (January 21, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain

Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on January 25, 2021).

EX-4.1 2 a20210121ex41formofwarrant.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 a8-k20210121pipedeal.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporati

Registration Rights Agreement, dated January 21, 2021, by and among the Company and the Investors (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on January 25, 2021).

EX-10.2 4 a20210121ex102formofregrts.htm EX-10.2 Exhibit 10.2 EXHIBIT A REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 21, 2021, by and between Caladrius Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease J a n u a r y 11 , 2 0 21 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements with

EX-99.1 2 clbscorppresentationjanu.htm EX-99.1 David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease J a n u a r y 11 , 2 0 21 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements refl

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Numb

David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease D e c e m b e r 2 0 20 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements within

ex991corporatepresentati David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease D e c e m b e r 2 0 20 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 a8-kcorporatedeck.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2020 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation

Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Program strategy and prioritization supports projection of available capital through 2021

Exhibit 99.2 Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Program strategy and prioritization supports projection of available capital through 2021 BASKING RIDGE, N.J. (December 14, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to re

Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

Exhibit 99.1 Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J. (November 17, 2020) ? Caladrius Biosciences, Inc. (Nasdaq: CLBS) (?Caladrius? or the ?Company?), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies desig

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Num